Renal cell carcinoma

Researchers are testing an experimental immunotherapy called GNR-051 in adults with advanced lung cancer, kidney cancer, or melanoma that has returned or not responded to other treatments. The Phase 1 trial aims to find the highest dose people can tolerate and to track side effec…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This trial tests whether combining the immunotherapy drug atezolizumab with precise, high-dose radiation (SABR) can better control metastatic cancers, including colorectal, lung, kidney, and sarcoma. The idea is that radiation may make tumors more visible to the immune system, wh…

This trial tests whether stereotactic ablative body radiation (SAbR), a precise form of high-dose radiation, can delay the need for systemic therapy in people with oligometastatic renal cell carcinoma, meaning kidney cancer that has spread to a few limited sites. Researchers will…

This phase 2 trial is testing whether adding precise, high-dose radiation (SBRT) to standard immunotherapy (ipilimumab and nivolumab) can help people with metastatic kidney cancer live longer without their disease getting worse. About 66 participants with intermediate or poor-ris…

This early-stage study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 150 adults with certain…

This phase 3 trial is comparing a combination of two drugs—nivolumab (an immunotherapy) and cabozantinib (a targeted therapy)—against the current standard drug sunitinib in people with advanced or metastatic kidney cancer who have not yet received systemic treatment. The main goa…

This phase II trial is testing whether combining the targeted drug ixazomib with two chemotherapy drugs (gemcitabine and doxorubicin) can shrink tumors or stop them from growing in patients with a rare and aggressive kidney cancer called renal medullary carcinoma. The study enrol…

This study looked at whether the drug cabozantinib can help people with advanced kidney cancer that got worse after initial treatment with immunotherapy. 127 participants received cabozantinib as a second-line therapy. The main goal was to see how many patients experienced tumor …

This trial is testing whether adding an experimental drug called HBI-8000 to the immunotherapy nivolumab can safely control advanced melanoma, kidney cancer, and non-small cell lung cancer. The study enrolls adults whose cancers have not responded to prior treatments. Researchers…

This pilot study is testing whether a rapid, timed sequence of different drugs can improve outcomes for people with advanced or inoperable clear cell kidney cancer. Participants first receive cabozantinib, then a combination of two immunotherapies (ipilimumab and nivolumab), foll…

This study tested a personalized vaccine made from a patient's own tumor cells fused with immune cells (dendritic cells) to treat stage IV kidney cancer. The vaccine was given with a drug called GM-CSF to boost immune response. The main goal was to check safety and side effects i…

This trial evaluates the Bitrack robotic system, designed to assist surgeons during laparoscopic kidney removal (partial or total) and prostate removal. The study includes 15 adults scheduled for these surgeries. The goal is to check if the robot works safely and effectively, as …

This early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…

This study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot…

This early-stage trial tests an experimental antibody called JS004, which targets a protein on immune cells called BTLA, to see if it can help the immune system fight advanced solid tumors like melanoma, kidney cancer, and bladder cancer. The study includes JS004 alone or combine…

This phase 2 trial tests an experimental drug called LDP, an anti-PD-L1 monoclonal antibody that helps the immune system attack cancer cells. It enrolls adults with muscle-invasive bladder cancer, non-clear cell kidney cancer, or advanced penile cancer. Participants receive LDP i…

This phase II trial tests the drug lenalidomide (CC-5013) in people with advanced or inoperable kidney cancer. Lenalidomide works by cutting off blood flow to tumors, which may stop or slow their growth. The study aims to see how many patients respond to treatment and what side e…

This phase 2 trial is testing a new drug called cadonilimab (AK104), either alone or combined with axitinib, as a first treatment for advanced or metastatic kidney cancer. The study includes two parts: one testing different doses of cadonilimab alone in various kidney cancer type…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This study tested a two-step treatment for medium-sized kidney tumors (4.1-7 cm). First, doctors blocked the tumor's blood supply, then froze it. The goal was to see if this approach is safe and works well. 25 adults with stage T1b kidney cancer took part. The main focus was on s…

This large phase 3 trial tested whether taking sorafenib or sunitinib after kidney cancer surgery could prevent the cancer from coming back. Nearly 2000 patients participated. Unfortunately, neither drug improved disease-free survival compared to a placebo, and they caused side e…

This study tested a combination of two experimental treatments for people with advanced kidney cancer that cannot be removed by surgery. The first is Pexa-Vec, a modified virus designed to infect and destroy cancer cells while also boosting the immune system. The second is cemipl…

This completed study looked at how well avelumab (BAVENCIO) plus axitinib (INLYTA) works for advanced kidney cancer in everyday medical practice. Researchers tracked 105 patients across multiple EU countries to see survival rates at 12 and 24 months. The goal was to understand th…

This early-phase study tested an experimental drug called APX005M added to two standard immunotherapies (nivolumab and ipilimumab) in 26 people with advanced melanoma or kidney cancer who had not received prior immune therapy. The main goals were to check safety and find the best…

This study observed 311 adults with advanced kidney cancer who received cabozantinib (a targeted therapy) plus nivolumab (an immunotherapy) as their first treatment. Researchers tracked how long patients lived and how long tumors stayed under control in real-world settings. The g…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This phase 3 trial compared a combination of two immunotherapy drugs (nivolumab and ipilimumab) against the standard drug sunitinib in over 1,000 people with untreated advanced or metastatic kidney cancer. The study measured how well the tumors shrank, how long patients lived wit…

This early-stage trial tested a drug called belzutifan in 29 people with advanced clear cell kidney cancer that had worsened after other treatments. The main goal was to check safety and find the right dose. Participants took belzutifan pills daily, and researchers monitored side…

This Phase 3 trial tested whether combining pembrolizumab (an immunotherapy) with epacadostat (a drug that boosts the immune response) works better than standard drugs (sunitinib or pazopanib) for people with advanced kidney cancer that hasn't been treated before. The study enrol…

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…

This study tested whether adding an immunotherapy drug (nivolumab) to a targeted therapy (tivozanib) helps people with advanced kidney cancer live longer without their cancer growing. The trial included 343 adults whose cancer had worsened after one or two prior treatments, inclu…

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

This study tested a combination of two drugs (cadonilimab and lenvatinib) given before surgery to 39 people with kidney cancer that was difficult to operate on while saving the kidney. The goal was to shrink the tumor enough to allow a partial, kidney-sparing surgery instead of r…

This early-phase study tested two immunotherapy drugs (spartalizumab and canakinumab) given before surgery to 17 people with localized clear cell kidney cancer. The main goal was to see if this approach was safe and did not delay surgery. The study also looked at how the drugs af…

This phase 2 trial tested the drug sunitinib in 21 patients with kidney cancer that had spread to the brain. The goal was to see if the drug could shrink brain tumors by blocking blood flow and cell growth. Researchers measured how many patients had a response after two treatment…

This study looked at how safe and effective the drug Cabozantinib is for people aged 70 and older with advanced kidney cancer. Researchers tracked side effects and tumor response in 100 participants. The goal was to see if this treatment works well in older patients who have alre…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This early-phase study tested a new drug called gevokizumab alongside standard cancer treatments in 167 adults with advanced colorectal, stomach, or kidney cancer that had spread. The goal was to find a safe and active dose and see if the combination could help control the diseas…

This study tested whether measuring drug levels in the blood can help doctors adjust doses of two common kidney cancer medications, sunitinib and pazopanib. The goal was to see if this personalized approach reduces side effects and keeps the cancer from growing longer than the st…

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body h…

This Phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent kidney cancer from coming back after surgery. Nearly 1,000 participants who had their kidney removed due to renal cell carcinoma received either pembrolizumab or a placebo. The st…

This study tested a new way to do stem cell transplants in 23 children with cancers that came back or didn't respond to treatment. The method removes certain immune cells from the donor's stem cells to help the child's body recover faster and fight infections better. The goal was…

This phase 3 trial tested whether combining the immunotherapy drug pembrolizumab with the targeted drug axitinib works better than the standard drug sunitinib alone for people with advanced kidney cancer. Over 860 patients took part. The combination helped patients live longer an…

This study tested a personalized vaccine made from a patient's own tumor cells mixed with immune cells from a healthy donor. The goal was to see if the vaccine is safe and can help the immune system attack advanced kidney cancer. Forty people with stage IV kidney cancer took part…

This early-phase trial tested an experimental drug called BMS-986315, alone or combined with other immunotherapies (nivolumab or cetuximab), in 44 people with advanced solid tumors like head and neck, lung, or kidney cancer. The main goals were to check safety and find the right …

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 160 people with a rare type of advanced kidney cancer (non-clear cell renal cell carcinoma) that had not been treated before. The goal was to see if the drugs could shrink tumors. The study found that …

This early-phase trial tested a new treatment called CTX131 for adults with advanced solid tumors that have not responded to standard therapies. The treatment uses donor immune cells that are gene-edited to target a protein called CD70 found on cancer cells. The study enrolled 19…

This phase 3 trial tested whether combining the immunotherapy toripalimab with the targeted drug axitinib works better than the standard drug sunitinib for people with advanced kidney cancer that cannot be removed by surgery. Over 400 participants received either the combination …

This study tested whether adding special agents (FloSeal® or Surgicel®) to standard suturing during partial nephrectomy reduces bleeding and other complications. 150 patients with localized kidney tumors were randomly assigned to one of three groups. The main outcomes were bleedi…

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This study tested an experimental drug called BDB001 in people with advanced solid tumors (like skin, lung, or kidney cancer) that had stopped responding to standard immunotherapy. The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person took part, …

This study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study tested a new drug called ARO-HIF2 in 26 people with advanced clear cell kidney cancer that had gotten worse after other treatments. The main goal was to find a safe dose and check for side effects. This is an early-phase trial, so it focuses on safety and dosing, not y…

This phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than standard treatments for people with advanced non-clear cell kidney cancer. About 316 participants received either the drug combo or standard therapy. The main goal was…

This phase 3 trial tested whether the drug everolimus could prevent kidney cancer from coming back after surgery. Over 1,500 patients with high-risk kidney cancer took either everolimus or a placebo daily for 54 weeks. The study found a small improvement in recurrence-free surviv…

This study tested whether transplanting gut bacteria from people who responded well to immunotherapy could help others with advanced kidney cancer respond better. Fifty participants received either a fecal transplant or a placebo. The goal was to see if the transplant could slow …

This early-phase study tested stereotactic radiotherapy, a precise type of radiation, on 13 people with small kidney cancers (≤4 cm). The goal was to find the highest safe dose by gradually increasing the radiation in four steps. Participants were followed for up to 5 years to mo…

This phase 3 trial tested whether removing the kidney (nephrectomy) before taking the drug sunitinib helps people with metastatic kidney cancer live longer compared to taking sunitinib alone. 452 patients were randomly assigned to either surgery plus sunitinib or sunitinib only. …

This early-stage trial tested an experimental drug called EVT801 in 32 adults with advanced solid tumours that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose to use in future studies. Participants took EVT801 cap…

This study looked at whether taking the kidney cancer drug cabozantinib with a light breakfast changes how much drug gets into the body. Twelve patients with advanced kidney cancer took the drug both on an empty stomach and with a light breakfast, and researchers measured drug le…

Researchers are studying whether features from pretreatment 18F-FDG PET/CT scans can predict how well people with metastatic kidney cancer respond to first-line targeted therapy plus immunotherapy. The study reviews medical records and imaging data from 228 patients treated at a …

This completed study tested whether a special type of MRI (multiparametric MRI) can accurately tell the difference between benign and malignant small kidney tumors. About 387 adults with small solid kidney masses (1.5-4 cm) were scanned before surgery or biopsy. The goal was to s…

This study collects blood, tissue, and urine from about 589 people with different types of kidney or urinary tract tumors, plus healthy volunteers. Researchers are looking for special DNA markers (methylated DNA) that could help detect these cancers earlier and more accurately. T…

This study tested whether a special type of MRI, called perfusion MRI, can help doctors find and diagnose kidney tumors more accurately. 75 people with kidney cancer or suspected kidney tumors took part. The goal was to see if this imaging method could predict tumor type and how …

This completed study tested whether combining PET/MRI scans with machine learning could better assess how aggressive prostate cancer and other solid tumors are. Researchers enrolled 50 adults with prostate cancer, liver cancer, brain tumors, or kidney cancer. The goal was to see …

This pilot study tested a special PET scan method to see if it could detect early signs that targeted therapy is working for genitourinary cancer. Eleven patients had scans before and two weeks after starting treatment. The goal was to see if changes in tumor blood flow could pre…

This study tested a new radioactive imaging agent, 68Ga-OncoCAIX, in 20 people with a type of kidney cancer called clear cell renal cell carcinoma. The goal was to see if it is safe and how it spreads in the body. Researchers measured radiation doses to organs and checked for sid…

This trial tests whether a structured patient education program can lower the risk of severe immune-related side effects in people receiving immunotherapy for certain cancers, including melanoma, lung, kidney, and head and neck cancers. Participants either attend five educational…

This study tested whether using a 3D model of a patient's kidney before surgery could shorten the time needed for robotic-assisted partial nephrectomy (removing a kidney tumor). 370 adults with small kidney tumors took part. The goal was to see if better planning with 3D imaging …

This study looked at 98 adults who had kidney removal surgery to see which pain-blocking method works better: a paravertebral block or an external oblique intercostal block. Both are injections that numb nerves to reduce pain after surgery. The goal was to find which one leads to…

This study tested a fast-recovery program for people having minimally invasive kidney surgery (laparoscopic or robotic) to remove tumors. The goal was to see if the program could safely shorten hospital stays by at least one day. Sixty patients took part, and researchers tracked …

This study tested whether a smartphone app could help patients with advanced kidney cancer learn about and manage side effects from combination immunotherapy. Twenty patients used the app for six weeks. The goal was to see if patients found the app helpful and if it improved thei…

Researchers want to learn which molecules on cancer cells the immune system attacks when checkpoint inhibitor drugs work well. They collect tumor and blood samples from adults with solid tumors who respond to these drugs, either during treatment or after surgery. The team then se…

This study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…

This trial tests whether a 15-minute educational video and a list of suggested questions can improve understanding of immunotherapy among patients with advanced cancer and their caregivers. Participants are randomly assigned to receive the educational materials or usual care, and…

This completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…

This completed study examined whether a specific variation in the VEGF gene (rs699947) is linked to a higher risk of developing kidney cancer in people who have received a kidney transplant. Researchers analyzed DNA from 272 transplant patients, some of whom had kidney cancer. Th…

This completed study created a registry of 28 patients with TFE renal cell carcinoma, a rare kidney cancer. Researchers collected medical data, tumor samples, and images to better understand the disease. The goal is to use this information to guide future research and develop mor…

This study reviewed medical records of 494 adults with advanced kidney cancer who received immunotherapy as their first treatment. Researchers looked at how long patients stayed on treatment, how they responded, and survival rates. The goal was to understand which treatment combi…

This study followed 623 adults in France with advanced kidney cancer who were starting treatment with the immunotherapy drugs nivolumab (with or without ipilimumab) for the first time. Unlike a clinical trial, this was an observational study that simply tracked what happened in e…

This study looked at how lifestyle factors like obesity and muscle loss affect kidney cancer risk and survival after kidney removal. Researchers collected blood, tissue, and questionnaire data from 161 patients over up to 5 years. The goal was to understand how to personalize tre…

This completed research study collected and stored tumor tissue, blood, and urine samples from 8,000 children and young adults with kidney tumors. The goal was to help scientists study DNA changes and find biomarkers that could improve understanding of these cancers. No treatment…

This study tested whether implanting tiny gold markers near spinal tumors helps deliver radiation more accurately. Researchers also checked if giving slightly more radiation to the nearby esophagus is safe, which might improve tumor control. The study involved 41 adults with vari…

This study looked at whether a software program called Carevive could help patients with advanced kidney cancer track side effects from their oral targeted therapy or immunotherapy. 21 patients used the software to report symptoms and received self-care tips. The goal was to see …

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…

This study tested whether 3D ultrasound can accurately measure kidney and tumor volumes compared to standard CT or MRI scans. 53 adults with chronic kidney disease or kidney tumors participated. Researchers compared 3D ultrasound measurements to those from contrast-enhanced CT or…

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving their first immunotherapy treatment could successfully collect small blood samples at home using a finger-prick method. The goal was to see if this approach is practical and rel…

This completed study looked at how kidney cancers are found—either because a patient had symptoms or by chance during a scan for something else. Researchers reviewed 1000 patients who had surgery for kidney lesions in the Czech Republic. The goal was to see which detection method…

This study looked at how patients with advanced kidney cancer fared when taking the drug axitinib after first trying sunitinib. Researchers did not give any new treatment—they simply observed 554 patients to see how long the drug worked and how long patients stayed on it. The goa…

This study explored whether small particles called exosomes, found in blood and urine, can help predict how well treatment works in people with advanced kidney cancer. Researchers followed 91 patients for 16 weeks, collecting samples and comparing them to imaging results. The goa…

This study involved 91 adults with advanced kidney cancer. Researchers collected blood and urine samples over 16 weeks to see if changes in tiny particles called exosomal miRNAs could predict whether treatment was working. The goal was to find a simple, non-invasive way to monito…

This completed study collected blood and tumor tissue from 64 patients with advanced cancers (like melanoma, breast, lung, and kidney cancer) to study genetic changes and treatment resistance. The samples are stored for future research, including genomic analysis. No new treatmen…

This completed study looked back at the medical records of 200 patients with advanced clear cell kidney cancer who received Tivozanib as their first treatment. The goal was to see how long patients went without their cancer getting worse and how long they lived overall. The study…

This study tested whether using at-home monitoring devices (like a wristband pedometer, scale, and blood pressure cuff) can help improve care for cancer patients after they leave the hospital following surgery. 22 patients with various cancers participated. The goal was to see if…

This completed study enrolled 43 people with kidney cancer who were starting sunitinib (Sutent). Researchers measured the drug's level in the blood and checked for genetic differences that might affect how the body processes it. The goal was to understand why sunitinib levels var…

This study tested a new surgical approach for removing kidney tumors using a robot. It compared the new method to the standard one in 40 adults. The goal was to see if the new method saves time and feels better for the surgeon.

This completed study looked at 327 adults with advanced kidney cancer who received one of two drug combinations (nivolumab+ipilimumab or pembrolizumab+lenvatinib) in real-world U.S. clinics. Researchers collected data on patient characteristics, treatment patterns, and outcomes f…

This study tested whether analyzing the DNA and RNA of a child's tumor could help doctors choose personalized treatments. It included 186 children with relapsed or hard-to-treat cancers like neuroblastoma and brain tumors. The goal was to see if this approach was feasible and saf…

This completed study tested whether a computer model could predict a rare type of kidney cancer (MIT family translocation kidney cancer) from standard CT scans. Researchers analyzed data from 746 patients with kidney cancer, using AI to find patterns in the scans that might indic…